OrbiMed

OrbiMed is a global healthcare specialist investor that backs companies across the full healthcare lifecycle, from incubation and seed through public crossover, growth, and non-dilutive royalty/credit financings. The firm is known for deep scientific and commercial diligence, a willingness to lead and take board seats, and flexible capital deployment across biopharma, devices, diagnostics/tools, and tech-enabled healthcare services.

Evaluation weights

How much weight this investor places on each dimension. Totals 100%.

Product-led · 36%

Metrics

10%

Revenue, growth, and unit economics

Market

25%

Size, timing, and competitive landscape

Team

29%

Founder experience and execution ability

Product

36%

Differentiation and technical quality

Bias toward healthcare opportunities where specialist diligence creates an edge
Preference for lead positions with governance influence
Willingness to fund early risk if scientific conviction is high
Stronger interest in flexible financing structures when cash flows are durable

Pitch difficulty

How hard it is to get a meeting and close funding from this investor.

Funded / yr

Deals closed in a typical year.

Led / yr

Rounds led in the last 12 months.

Pitches / yr

~1500

Decks reviewed in a typical year.

Acceptance rate

1.0%

Share of pitches that get funded.

Estimated — public data is not fully disclosed.

Why it's hard

Deep specialist diligence on science, clinical evidence, and management
Focus on category-defining healthcare innovation rather than incremental products
Frequent preference to lead rounds and take board seats
Low tolerance for weak data, unclear regulatory pathways, or governance issues

OrbiMed is highly selective because it is a specialist healthcare investor that performs deep domain diligence, often leads rounds, and holds a high bar for scientific quality, regulatory clarity, management strength, and governance. Its broad stage coverage does not make it easy to access; rather, it reflects the firm's ability to choose only the best-fit healthcare opportunities across many financing types.

Green flags

What drives a yes for this investor.

High-quality, reproducible science or technical evidence validated through deep diligence
A credible management team capable of navigating development, regulation, and commercialization
Clear regulatory pathway with identifiable value-inflection milestones
Strong commercial rationale, including workflow fit or scalable go-to-market design
Ability for OrbiMed to lead, influence governance, and support the company across multiple financings

Red flags

What kills deals and gets a fast no.

Irreproducible science or overstated technical claims
Ambiguous regulatory strategy or unrealistic development timelines
Weak governance, poor incentive alignment, or inability to support board-level oversight
Commercial model with unclear reimbursement, buyer adoption, or workflow fit
Raising a financing structure that does not match the company’s maturity or risk profile

How to win

Patterns that lead to successful pitches.

Show a rigorous data package tailored to healthcare specialists, not generalist investors
Present a crisp regulatory and milestone roadmap with clear value-inflection points
Demonstrate why the team can execute through the next phase of development and commercialization
For diagnostics/digital health, prove workflow integration and clinical utility with real users or customers
For later-stage opportunities, emphasize revenue durability, cash-flow visibility, and financing fit

Fund strategy & identity

Who they are and how they operate.

Invest across the full lifecycle from Pre-Seed to Growth and crossover/public opportunities
Lead rounds in breakthrough healthcare companies, especially where OrbiMed can shape governance and strategy
Use multiple capital formats—equity, private credit, and royalty financing—based on company maturity and risk profile
Concentrate on four core healthcare verticals: biopharma, medical devices, diagnostics/tools, and tech-enabled services
Scale exposure over time as clinical, regulatory, and commercial milestones reduce risk

Firm identity

Global healthcare-only investment platform Deep domain diligence across science, regulation, and commercialization Flexible multi-platform investor spanning venture, growth, public equity, credit, and royalties High-conviction lead investor with board-level involvement Comfortable incubating companies and scaling capital as risk de-risks

Investment focus

Industries, themes, and typical ARR expectations.

Industries

BiopharmaceuticalsMedical DevicesDiagnosticsResearch and Clinical ToolsTech-enabled Healthcare ServicesHealthcare IT / Digital HealthRoyalty and Credit for Commercial-stage Healthcare Companies

Investment themes

Scientifically novel therapeutics with category-defining potentialMedical devices with differentiated clinical outcomes and adoption pathwaysDiagnostics and research/clinical tools with clear clinical utilityTech-enabled healthcare services integrated into provider or payer workflowsCommercial-stage healthcare companies suited for royalty or credit financingGlobal healthcare innovation across North America, Europe, and Asia

Typical check by stage

Seed$5M-$15M

Series A$10M-$40M

Series B$15M-$60M

Series C$15M-$50M

Growth$25M-$150M

Typical ARR by stage

Pre Seed$0

Seed$0-$1M

Series A$0-$2M

Series B$0-$5M

Series C$0-$25M

Growth$10M-$50M+

Investment thesis

Core beliefs and strategy behind their investing approach.

OrbiMed’s investment thesis is to back innovative, growth‑oriented healthcare companies across the full life‑cycle, pairing deep domain diligence with flexible capital to compound value as products de‑risk and scale. The firm invests globally – North America, Europe and Asia – in four main sub‑sectors: biopharmaceuticals, medical devices, diagnostics/tools and technology‑enabled healthcare services. It deploys three platforms – public equity, private equity/venture and private credit/royalty – and typically acts as a lead investor, offering equity, credit and royalty‑based financing from seed/incubation through later‑stage growth. In therapeutics and tools, OrbiMed targets scientifically novel, category‑defining programs with rigorous data, clear regulatory pathways and strong commercial rationale, often incubating companies and scaling its commitment through successive rounds. In diagnostics and digital health, the focus is on differentiated clinical utility, workflow integration and scalable go‑to‑market models. The firm’s Royalty & Credit platform provides non‑dilutive capital to commercial‑stage companies, emphasizing predictable cash flows. OrbiMed integrates material ESG considerations but does not let them dominate decisions, and it avoids categorical sector bans, allowing flexibility to pursue emerging scientific opportunities while maintaining discipline around data quality, governance and alignment. Check sizes can reach up to ~$250 M per company when multiple funds are leveraged.

Decision patterns

How they evaluate and make investment decisions.

OrbiMed invests when deep diligence uncovers high‑quality science coupled with a strong, credible management team capable of advancing category‑defining programs. The firm favors opportunities that demonstrate clear regulatory pathways, robust clinical or technical data, and scalable go‑to‑market models. In diagnostics and digital health, demonstrated clinical utility and workflow integration are paramount; in later‑stage growth or royalty/credit deals, predictable revenue streams and cash‑flow durability dominate. OrbiMed typically leads rounds, takes board seats, and may incubate companies, reflecting a bias toward influence where conviction is strong. Deal‑breakers include irreproducible data, ambiguous regulatory routes, weak governance, or misaligned incentives. ESG considerations are incorporated when financially material but never primary. The firm balances team versus market versus traction differently by stage: early therapeutics weigh team and data highest, mid‑stage tools weigh market validation and traction, while credit/royalty investments prioritize revenue stability.

Risk appetite

OrbiMed adopts a balanced but assertive risk profile. It is comfortable leading high‑risk, high‑reward seed and Series A rounds in breakthrough therapeutics and platforms, while simultaneously providing downside‑protected credit and royalty financing to mature, revenue‑generating companies. The firm typically leads investments, takes board seats, and scales capital as risk de‑rises, resulting in a barbell strategy that blends aggressive early‑stage exposure with more conservative credit‑focused exposure.

Notable investments

Key portfolio companies and why they fit the thesis.

Odyssey TherapeuticsLead
Next-gen precision immunomodulators/oncology; large early-stage financing aligns with OrbiMed's biotech thesis and willingness to lead at formation.
AbCelleraLead
AI-enabled antibody discovery platform; OrbiMed co-led the Series B to scale a differentiated discovery engine.
Intellia TherapeuticsLead
CRISPR gene-editing pioneer; OrbiMed led the $70M Series B in September 2015 in a category-defining modality.
EvozyneLead
Generative AI for therapeutic protein design; co-led to back platform-scale innovation.
Aspen NeuroscienceLead
Autologous cell therapy for Parkinson's; clinical-stage, high-need asset co-led by OrbiMed.
Avenzo TherapeuticsLead
Oncology pipeline with best-in-class potential; OrbiMed co-led the Series B.
Sidewinder TherapeuticsLead
Next-gen bispecific ADCs; sole Series A investor, demonstrating OrbiMed's propensity to lead early biotech builds.
Guardant HealthLead
Liquid-biopsy leader; OrbiMed led the $100M Series D in January 2016 as the company scaled precision oncology diagnostics.
Pee SafeLead
Consumer health brand with strong ARR and profitability in India; fits OrbiMed's Asia strategy and tech-enabled health focus.
Adcendo
First-in-class ADC pipeline; OrbiMed participated alongside the lead investor, illustrating selective participation.

Key people

Partners who lead investments and shape the thesis.

CL
Carl L. Gordon
Managing Partner
TherapeuticsLife-sciences private equityVenture investing
SH
Sven H. Borho
Managing Partner
Public equityPrivate equityBiopharma
WC
W. Carter Neild
Managing Partner
Royalty financingCredit solutionsGrowth-stage investments
SS
Sunny Sharma
Partner and Senior Managing Director (Asia)
Asia private equityHealthcare servicesMedTechBiopharma

Public voice

Notable statements and public positions.

"Over 90% of Fund V's committed capital is from existing, long‑standing firm relationships," said Carter Neild, Managing Partner (Aug 4 2025).
"OrbiMed believes that there is a high congruence between companies that seek to act responsibly and those that succeed in building long‑term shareholder value," – OrbiMed Responsible Investing Policy.
"We conduct deep due diligence on both the science and the management team. We look for companies developing something truly innovative—programs that can change the course of medicine," said Carl Gordon, Managing Partner.

Similar investors

Firms with overlapping stage and industry focus.

RA Capital Management 2.0%

Shared focus

DiagnosticsMedical devices